CHICAGO — Kirk Shepard, MD, senior vice president, chief medical officer and head of global medical affairs for the oncology business group at Eisai, spoke with HemOnc Today at ASCO Annual Meeting about key data the company presented at the conference.
Shepard highlighted data from the SELECT trial related to the timing of treatment initiation with lenvatinib (Lenvima) for patients with advanced thyroid cancer.
“We know Lenvima is very effective as far as response rate ... but should we start it now or wait until later?” Shepard said. “These data tell us we should go ahead and start early.”
Shepard spoke about the potential of lenvatinib in combination with other immuno-oncology agents.
He also provided insights into other agents in Eisai’s pipeline. – by Mark Leiser